HPB Surgical Unit, Department of Surgery & Cancer, Imperial College, Hammersmith Hospital, Du Cane Road, London, UK.
Expert Rev Anticancer Ther. 2011 Dec;11(12):1837-42. doi: 10.1586/era.11.184.
microRNAs (miRs) are a recently recognized class of noncoding short RNAs, 17-25 nucleotides in length, that play a role in post-transcriptional gene regulation by translational repression and/or mRNA degradation. Various miRs have been highlighted in pancreatic cancer development and metastasis, and as potential clinical diagnostic/prognostic biomarkers. Recently, studies have indicated that miRs are responsible for resistance to chemotherapeutic agents. The miR-10b has been identified as a 'metastamiR' in various tumor types, notably breast cancer, but data surrounding its relevance in pancreatic ductal adenocarcinoma has been sparse. The evaluated article presents data indicating that miR-10b is upregulated in pancreatic ductal adenocarcinoma and can be used as a diagnostic marker in endoscopic ultrasound-guided fine-needle aspiration biopsies of suspicious pancreatic lesions. In addition, miR-10b may be able to guide neoadjuvant gemcitabine-based chemoradiotherapy and predict metastatic-free survival and overall survival.
微小 RNA（miRs）是一类新发现的非编码短 RNA，长度为 17-25 个核苷酸，通过翻译抑制和/或 mRNA 降解在转录后基因调控中发挥作用。各种 miR 在胰腺癌的发展和转移中被突出强调，并作为潜在的临床诊断/预后生物标志物。最近的研究表明，miRs 是导致对化疗药物耐药的原因。miR-10b 已被确定为多种肿瘤类型（尤其是乳腺癌）中的“转移 miR”，但围绕其在胰腺导管腺癌中的相关性的数据却很少。评估的文章提供的数据表明，miR-10b 在胰腺导管腺癌中上调，可作为内镜超声引导下可疑胰腺病变细针抽吸活检的诊断标志物。此外，miR-10b 可能能够指导基于吉西他滨的新辅助放化疗，并预测无转移生存和总生存。
